相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Design, synthesis and promising anti-tumor efficacy of novel imidazo [1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors
Hongrui Lei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2022)
Nucleotide pyrophosphatase/phosphodiesterases (NPPs) including NPP1 and NPP2/ATX as important drug targets: A patent review (2015-2020)
Sehrish Bano et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2022)
Structure-Based Design of a Novel Class of Autotaxin InhibitorsBased on Endogenous Allosteric Modulators
Jennifer M. Clark et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Roles of Autotaxin/Autotaxin-Lysophosphatidic Acid Axis in the Initiation and Progression of Liver Cancer
Sha She et al.
FRONTIERS IN ONCOLOGY (2022)
LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis
Benjamin E. Decato et al.
RESPIRATORY RESEARCH (2022)
Anti-cancer strategies targeting the autotaxin-lysophosphatidic acid receptor axis: is there a path forward?
Gabor Tigyi et al.
CANCER AND METASTASIS REVIEWS (2021)
Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study
Souvik Banerjee et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)
Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells
Elisa Matas-Rico et al.
CELL REPORTS (2021)
Design and Development of Autotaxin Inhibitors
Yi Jia et al.
PHARMACEUTICALS (2021)
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
Tamera J. Corte et al.
BMJ OPEN RESPIRATORY RESEARCH (2021)
Revisiting the role of lysophosphatidic acid in stem cell biology
Gabor Tigyi et al.
EXPERIMENTAL BIOLOGY AND MEDICINE (2021)
Recent Progress on Tubulin Inhibitors with Dual Targeting Capabilities for Cancer Therapy
Wen Shuai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of Potent Selective Nonzinc Binding Autotaxin Inhibitor BIO-32546
Bin Ma et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Disrupted Blood-Brain Barrier and Mitochondrial Impairment by Autotaxin-Lysophosphatidic Acid Axis in Postischemic Stroke
Susmita Bhattarai et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Lysophosphatidic Acid Signaling in Cancer Cells: What Makes LPA So Special?
Pravita Balijepalli et al.
CELLS (2021)
Optimization and evaluation of novel tetrahydropyrido[4,3-d] pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis
Nan Jiang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Dual-target kinase drug design: Current strategies and future directions in cancer therapy
Dejuan Sun et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of a Novel Dual-Target Inhibitor of ERK1 and ERK5 That Induces Regulated Cell Death to Overcome Compensatory Mechanism in Specific Tumor Types
Guan Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Novel Indole-Based Allosteric Highly Potent ATX Inhibitors with Great In Vivo Efficacy in a Mouse Lung Fibrosis Model
Hongrui Lei et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
A Perspective on Multi-target Drugs for Alzheimer's Disease
Ondrej Benek et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model
Yuzo Iwaki et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Regulation of Tumor Immunity by Lysophosphatidic Acid
Sue Chin Lee et al.
CANCERS (2020)
Conditional Lpar1 gene targeting identifies cell types mediating neuropathic pain
Richard R. Rivera et al.
FASEB JOURNAL (2020)
Novel Autotaxin Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis: A Clinical Candidate Discovered Using DNA-Encoded Chemistry
John W. Cuozzo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Molecular modelling guided design, synthesis and QSAR analysis of new small molecule non-lipid autotaxin inhibitors
Souvik Banerjee et al.
BIOORGANIC CHEMISTRY (2020)
Generation and trapping of a mesoderm biased state of human pluripotency
Dylan Stavish et al.
NATURE COMMUNICATIONS (2020)
Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds
Ewgenij Proschak et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Cink4T, a quinazolinone-based dual inhibitor of Cdk4 and tubulin polymerization, identified via ligand-based virtual screening, for efficient anticancer therapy
Vinay Sonawane et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy
Kinsie E. Arnst et al.
MEDICINAL RESEARCH REVIEWS (2019)
Osteoclast-Derived Autotaxin, a Distinguishing Factor for Inflammatory Bone Loss
Sacha Flammier et al.
ARTHRITIS & RHEUMATOLOGY (2019)
LPA5 Is an Inhibitory Receptor That Suppresses CD8 T-Cell Cytotoxic Function via Disruption of Early TCR Signaling
Divij Mathew et al.
FRONTIERS IN IMMUNOLOGY (2019)
Lysophosphatidic Acid Receptor 1 Antagonists for the Treatment of Fibrosis
Ahmed F. Abdel-Magid
ACS Medicinal Chemistry Letters (2019)
Autotaxin determines colitis severity in mice and is secreted by B cells in the colon
Songbai Lin et al.
FASEB JOURNAL (2019)
Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors
Tongfei Jing et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Role of autotaxin in cancer stem cells
Dongjun Lee et al.
CANCER AND METASTASIS REVIEWS (2018)
Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study
Yannick Allanore et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
Scott M. Palmer et al.
CHEST (2018)
Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis
Ioanna Ninou et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Autotaxin in Pathophysiology and Pulmonary Fibrosis
Joanna Ninou et al.
FRONTIERS IN MEDICINE (2018)
Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors
Tatu Pantsar et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2017)
Maternal serum autotaxin levels in early- and late-onset preeclampsia
Hakan Erenel et al.
HYPERTENSION IN PREGNANCY (2017)
Computational Multitarget Drug Design
Weilin Zhang et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)
Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells
Souvik Banerjee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Structure-Activity Relationships of Small Molecule Autotaxin Inhibitors with a Discrete Binding Mode
Lisa M. Miller et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Autotaxin-Lysophosphatidic Acid: From Inflammation to Cancer Development
Silvia Anahi Valdes-Rives et al.
MEDIATORS OF INFLAMMATION (2017)
Discovery of potent inhibitors of the lysophospholipase autotaxin
Pritom Shah et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Autotaxin Regulates Maintenance of Ovarian Cancer Stem Cells through Lysophosphatidic Acid-Mediated Autocrine Mechanism
Eun Jin Seo et al.
STEM CELLS (2016)
The role of platelets and megakaryocytes in bone metastasis
Raphael Leblanc et al.
JOURNAL OF BONE ONCOLOGY (2016)
Crystal Structure of Antagonist Bound Human Lysophosphatidic Acid Receptor 1
Jill E. Chrencik et al.
CELL (2015)
Lysophosphatidate signaling stabilizes Nrf2 and increases the expression of genes involved in drug resistance and oxidative stress responses: implications for cancer treatment
Ganesh Venkatraman et al.
FASEB JOURNAL (2015)
Lysophosphatidic Acid Signaling in the Nervous System
Yun C. Yung et al.
NEURON (2015)
The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer
Debashish Sahay et al.
ONCOTARGET (2015)
Autotaxin and LPA1 and LPA5 Receptors Exert Disparate Functions in Tumor Cells versus the Host Tissue Microenvironment in Melanoma Invasion and Metastasis
Sue-Chin Lee et al.
MOLECULAR CANCER RESEARCH (2015)
The Bulk of Autotaxin Activity Is Dispensable for Adult Mouse Life
Aggeliki Katsifa et al.
PLOS ONE (2015)
Methods for quantifying lysophosphatidic acid in body fluids: A review
Anna Jesionowska et al.
ANALYTICAL BIOCHEMISTRY (2014)
Lysophosphatidic acid receptor inhibition as a new multipronged treatment for rheumatoid arthritis
Beatriz Orosa et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone
Raphael Leblanc et al.
BLOOD (2014)
Targeting the hydrophobic pocket of autotaxin with virtual screening of inhibitors identifies a common aromatic sulfonamide structural motif
James I. Fells et al.
FEBS JOURNAL (2014)
Strategies for modern biomarker and drug development in oncology
Alan D. Smith et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Lysophosphatidic Acid Receptor 5 Inhibits B Cell Antigen Receptor Signaling and Antibody Response
Jiancheng Hu et al.
JOURNAL OF IMMUNOLOGY (2014)
Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis
Sydney B. Montesi et al.
BMC PULMONARY MEDICINE (2014)
Screening and X-ray Crystal Structure-based Optimization of Autotaxin (ENPP2) Inhibitors, Using a Newly Developed Fluorescence Probe
Mitsuyasu Kawaguchi et al.
ACS CHEMICAL BIOLOGY (2013)
Necessity of Lysophosphatidic Acid Receptor 1 for Development of Arthritis
Yoshishige Miyabe et al.
ARTHRITIS AND RHEUMATISM (2013)
Lysophosphatidic acid: Chemical signature of neuropathic pain
Hiroshi Ueda et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
A Metabolically-Stabilized Phosphonate Analog of Lysophosphatidic Acid Attenuates Collagen-Induced Arthritis
Ioanna Nikitopoulou et al.
PLOS ONE (2013)
Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression
Shannon K. Oda et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis
Ioanna Nikitopoulou et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Autotaxin induces lung epithelial cell migration through lysoPLD activity-dependent and -independent pathways
Jing Zhao et al.
BIOCHEMICAL JOURNAL (2011)
Structure-Based Design of Novel Boronic Acid-Based Inhibitors of Autotaxin
Harald M. H. G. Abers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Structural basis of substrate discrimination and integrin binding by autotaxin
Jens Hausmann et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Crystal structure of autotaxin and insight into GPCR activation by lipid mediators
Hiroshi Nishimasu et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
A novel, orally active LPA1 receptor antagonist inhibits lung fibrosis in the mouse bleomycin model
J. S. Swaney et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Improved method for the quantification of lysophospholipids including enol ether species by liquid chromatography-tandem mass spectrometry
James G. Bollinger et al.
JOURNAL OF LIPID RESEARCH (2010)
Optimization of a Pipemidic Acid Autotaxin Inhibitor
Adrienne B. Hoeglund et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery and Optimization of Boronic Acid Based Inhibitors of Autotaxin
Harald M. H. G. Albers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Expression of Autotaxin and Lysophosphatidic Acid Receptors Increases Mammary Tumorigenesis, Invasion, and Metastases
Shuying Liu et al.
CANCER CELL (2009)
Dual Activity Lysophosphatidic Acid Receptor Pan-Antagonist/Autotaxin Inhibitor Reduces Breast Cancer Cell Migration In vitro and Causes Tumor Regression In vivo
Honglu Zhang et al.
CANCER RESEARCH (2009)
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Piyush B. Gupta et al.
CELL (2009)
Virtual screening approaches for the identification of non-lipid autotaxin inhibitors
Abby L. Parrill et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Quantitative determination of lysophosphatidic acid by LC/ESI/MS/MS employing a reversed phase HPLC column
Lian Shan et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2008)
Multi-target-directed ligands to combat neurodegenerative diseases
Andrea Cavalli et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Albumin-Associated Lipids Regulate Human Embryonic Stem Cell Self-Renewal
Francesc R. Garcia-Gonzalo et al.
PLOS ONE (2008)
Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis
Daniel L. Baker et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity
CG Ferguson et al.
ORGANIC LETTERS (2006)
Designed multiple ligands. An emerging drug discovery paradigm
R Morphy et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation -: Up-regulated expression with adipocyte differentiation and obesity
G Ferry et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production
M Umezu-Goto et al.
JOURNAL OF CELL BIOLOGY (2002)
Production and application of LPA polyclonal antibody
JH Chen et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
分享论文
